Early Use of Newer Agents for Advanced Non-Small-Cell Lung Cancer - Goulart, Bernardo
35,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
18 °P sammeln
  • Broschiertes Buch

Background: Previous studies have reported on the patterns of use of first-line chemotherapy with platinum doublets in advanced NSCLC. There are no studies of patterns of use of newer agents in advanced NSCLC. We evaluated the nationwide incidence and predictors of use of new agents including bevacizumab, erlotinib, and pemetrexed. Methods: We retrospectively selected patients with stage IIIB/IV NSCLC diagnosed in 2005 from a random sample drawn from SEER registries to abstract data on clinical and socio-demographic factors and types of anti-cancer drug regimens for up to two years from…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Background: Previous studies have reported on the patterns of use of first-line chemotherapy with platinum doublets in advanced NSCLC. There are no studies of patterns of use of newer agents in advanced NSCLC. We evaluated the nationwide incidence and predictors of use of new agents including bevacizumab, erlotinib, and pemetrexed. Methods: We retrospectively selected patients with stage IIIB/IV NSCLC diagnosed in 2005 from a random sample drawn from SEER registries to abstract data on clinical and socio-demographic factors and types of anti-cancer drug regimens for up to two years from diagnosis. We used descriptive statistics to report the incidence of use of bevacizumab, erlotinib, and pemetrexed. We used multiple logistic regression to detect predictors of treatment with these new agents.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Bernardo H. L. Goulart nació en Río de Janeiro (Brasil) en 1974. Se licenció en medicina en Brasil. Tras trasladarse a Estados Unidos, realizó una residencia en medicina interna y una beca en oncología médica en la Universidad de Washington, donde trabaja actualmente.